Telix Pharmaceuticals (TLX) vs Tango Therapeutics (TNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tango Therapeutics (TNGX) has outperformed Telix Pharmaceuticals (TLX) over the past year, gaining 226.6% versus a gain of 7.5%. Tango Therapeutics is the larger company by market cap ($3.81 billion vs $3.74 billion), about 1.0 times the size, while Telix Pharmaceuticals is growing revenue faster (+55.6% vs +48.3%). Telix Pharmaceuticals converts more of its revenue into profit, with a net margin of -0.9% versus -162.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TLX | TNGX |
|---|---|---|
| Share price | $11.01 | $22.57 |
| Market cap | $3.74B | $3.81B |
| 1-day change | -0.99% | +3.39% |
| YTD return | +47.00% | +154.74% |
| 1-year return | +7.52% | +226.63% |
| 5-year return | — | +60.87% |
| P/E ratio (TTM) | 110.10 | — |
| EPS (TTM) | $0.10 | $-0.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $803.79M | $62.38M |
| Revenue growth (YoY) | +55.61% | +48.29% |
| Net income (latest FY) | $-7.13M | $-101.59M |
| Gross margin | 53.05% | — |
| Operating margin | 3.70% | -178.39% |
| Net margin | -0.89% | -162.85% |
| 52-week high | $13.11 | $34.39 |
| 52-week low | $6.28 | $6.69 |
| Distance from 52-week high | -16.02% | -34.37% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +85.47% | +100.18% |
| Average volume | 261.67K | 2.65M |
| Shares outstanding | 339.78M | 168.61M |
| Employees | 1,120 | 137 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNGX has outperformed TLX by 219.1 percentage points over the past year.
- Telix Pharmaceuticals is more profitable, keeping -0.9 cents of every revenue dollar as net income versus -162.9 cents for Tango Therapeutics.
- Telix Pharmaceuticals grew revenue faster in its latest fiscal year (+55.61% vs +48.29%).
About Telix Pharmaceuticals
TLX stock →Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
TLX vs TNGX FAQ
Which is bigger, Telix Pharmaceuticals or Tango Therapeutics?
Tango Therapeutics (TNGX) is larger, with a market capitalization of $3.81B compared with $3.74B for Telix Pharmaceuticals (TLX).
Which stock has performed better over the past year, TLX or TNGX?
TNGX returned +226.63% over the past 12 months, compared with +7.52% for TLX (price return, excluding dividends). Past performance does not predict future results.
Are Telix Pharmaceuticals and Tango Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.